Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...

Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

Researchers found that patients who took statins alongside apalutamide and standard hormone therapy had higher three-year ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers.

Combining the PARP1-selective inhibitor saruparib with an androgen receptor pathway inhibitor (ARPI) demonstrated promising efficacy and safety in patients with metastatic prostate cancer, according ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...